{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:45:18Z","timestamp":1778622318515,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common toxicities associated with immunotherapies, including T cell redirecting bispecific antibodies. Although cooperative group guidelines recommend the use of tocilizumab or other IL-6\/IL-6R inhibitors for the management of CRS and ICANS, reports on the use of siltuximab, an IL-6 inhibitor, for the treatment of CRS are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed\/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and Outcome<\/jats:title>\n                    <jats:p>The patient received an infusion of siltuximab. The patient recovered from CRS within 1\u2005h of siltuximab administration and ICANS within 7\u2005h of siltuximab administration. Patient tolerated the subsequent dose of talquetamab with no evidence of CRS and continued on study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case describes the successful use of siltuximab for the management of CRS in a patient treated with a T cell redirecting bispecific antibody for RRMM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221140320","type":"journal-article","created":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T23:24:53Z","timestamp":1670196293000},"page":"1006-1010","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting"],"prefix":"10.1177","volume":"29","author":[{"given":"Brea C","family":"Lipe","sequence":"first","affiliation":[{"name":"University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,12,4]]},"reference":[{"key":"bibr1-10781552221140320","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194593"},{"key":"bibr2-10781552221140320","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S150524"},{"key":"bibr3-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511"},{"key":"bibr4-10781552221140320","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.229781"},{"key":"bibr5-10781552221140320","unstructured":"FDA. Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19. FDA. Published June 28, 2021. Accessed October 18, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19."},{"key":"bibr6-10781552221140320","unstructured":"Press Release: Roche Group. Roche statement on global supply constraints of Actemra\/RoActemra. Accessed October 18, 2021. https:\/\/www.roche.com\/dam\/jcr:a42a1844-a83e-470d-bebb-9badc8344d89-20210816_Roche%20statement%20global%20Actemra%20supply.pdf."},{"key":"bibr7-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8015"},{"key":"bibr8-10781552221140320","volume-title":"Hemel Hempstead, Hertfordshire","author":"SYLVANT (siltuximab) [package insert]"},{"key":"bibr9-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20270"},{"key":"bibr10-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1993.tb18138.x"},{"key":"bibr11-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"bibr12-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547"},{"key":"bibr13-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02148-6"},{"key":"bibr14-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"bibr15-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"bibr16-10781552221140320","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973"},{"key":"bibr17-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131123"},{"key":"bibr18-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124750"},{"key":"bibr19-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131300"},{"key":"bibr20-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"bibr21-10781552221140320","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8504"},{"key":"bibr22-10781552221140320","unstructured":"The University of Texas MD Anderson Cancer Center. IEC Therapy Toxicity Assessment and Management (also known as CARTOX) Adult. Accessed October 7, 2022. https:\/\/www.mdanderson.org\/content\/dam\/mdanderson\/documents\/for-physicians\/algorithms\/clinical-management\/clin-management-cytokine-release-web-algorithm.pdf."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221140320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221140320","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221140320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:40Z","timestamp":1777688860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221140320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/10781552221140320"],"URL":"https:\/\/doi.org\/10.1177\/10781552221140320","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,4]]}}}